Mediomics receives additional $460,000 in STTR Phase II grant for PINCER protein assay development

Mediomics, LLCJul 28 2010

Mediomics, LLC has received an additional $460,000 in a renewal of its 2^nd year STTR Phase II grant (R42GM079891) from the National Institute of General Medical Sciences. Since 2007, Mediomics has received over one million dollars of STTR funding to develop its quick and sensitive homogenous PINCER™ protein assay. The major goal of the second year project is to further increase the sensitivity of the biosensor.

“We expect in particular to achieve breakthroughs in sensitivity levels, making this a very attractive alternative to many products on the market, such as ELISA-based detecting technologies.”

Mediomics is currently focused on developing a sustainable, profitable biotechnology business that provides innovative assay kits, biosensors and microarrays for academic and corporate research, point of care testing, food and pharmaceutical production process control, as well as the medical and environmental research markets. These assay kits will be used to quantify most biologically and therapeutically important macromolecules, including ligands, proteins, protein complexes and pathogens. By 2012, it has been estimated that the global market for biosensors will reach approximately $6.1 billion dollars.

The company's rapid, mix-and-measure homogeneous assays have already been adapted for the detection of a range of biologically and therapeutically important macromolecules, including cAMP, tryptophan, S-adenosyl methionine, PDE assay, biotin, human insulin, C-peptide, human albumin, human C-reactive protein (hCRP), IgG, IgM, E. Coli and others.

"The grant will be enormously helpful as we continue to develop fast (5-30 min), simple (mix and measure), robust (CV<10%) and cost effective biosensors for detecting biomarkers, toxins and pathogens," said Mediomics President, Dr. Yie-Hwa Chang. "We expect in particular to achieve breakthroughs in sensitivity levels, making this a very attractive alternative to many products on the market, such as ELISA-based detecting technologies."